This article is part of a Chronicle. See more from this Chronicle
David Hull, Nov 12, 2008
Efforts by innovative pharmaceutical companies to protect their markets against generic drugs have generated a wide-ranging debate over how to achieve the proper balance between these companies legitimate interests in reaping the full rewards of their research and development (R&D) efforts and the public’s interest in having access to cheaper drugs. In Europe, this debate has largely centered on
...THIS ARTICLE IS NOT AVAILABLE FOR IP ADDRESS 3.137.174.216
Please verify email or join us to access premium content!